1,220 results match your criteria: "Candidiasis Chronic Mucocutaneous"
Mycopathologia
December 2024
Dermatology Hospital, Southern Medical University, Guangzhou, China.
We presented a case of chronic mucocutaneous candidiasis (CMC) due to STAT1 GOF mutation with recurrent enteritis and intestinal obstruction. A 33-year-old woman complained of recurrent oral erosion and finger (toe) nails damage for over 30 years. Candida albicans were cultured from the oral mucosa and nails.
View Article and Find Full Text PDFDermatol Reports
November 2024
Department of Dermatology, College of Medicine, King Saud University and King Saud University Medical City, Riyadh, Saudi Arabia.
Chronic mucocutaneous candidiasis (CMC) is a primary immunodeficiency condition caused by a genetic abnormality that increases the risk of recurrent and persistent skin, nail, and mucous membrane infections with Candida species, typically . Signal transducer and activator of transcription 1 (STAT1) gene mutation is a genetic trigger that causes CMC, which increases the risk of infections, multisystem disorders, and cancer susceptibility. We describe the first case of a Saudi female patient with clinical features of CMC with an underlying (STAT1) gene mutation.
View Article and Find Full Text PDFAm J Trop Med Hyg
November 2024
Laboratory of Immunology and Molecular Biology, Federal University of Sergipe, Aracaju, Brazil.
This report documents the first known cases of lepromatous leprosy in patients with chronic mucocutaneous candidiasis (CMC) linked to a gain-of-function mutation in the STAT1 gene. Two related patients, a mother and daughter, who both suffer from CMC and lepromatous leprosy, carry a heterozygous STAT1 mutation (c.821G>A; p.
View Article and Find Full Text PDFCurr Opin Allergy Clin Immunol
December 2024
Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Purpose Of Review: The identification of STAT1 gain-of-function (GOF) in 2011 and STAT3 GOF in 2014 has advanced our understanding of the host immunity along the JAK/STAT pathway and allowed targeted treatment approaches. We review the clinical features and pathogenesis of STAT1 and STAT3 GOF and how this has shaped new approaches to therapy.
Recent Findings: STAT1 GOF, initially described in patients with chronic mucocutaneous candidiasis (CMC) and autoimmune thyroid disease, is now recognized to cause early-onset multisystem autoimmunity and a range of infections.
Tunis Med
October 2024
Laboratory of Clinical Immunology, Inflammation, and Allergy (LICIA), Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco.
J Clin Immunol
October 2024
Laboratory of Immune Deficiencies, National Institute of Pediatrics Mexico City, Mexico City, Mexico.
Allergol Select
October 2024
Center for Child and Adolescent Health, Helios Hospital Krefeld, Academic Hospital of RWTH Aachen, Krefeld.
JCEM Case Rep
October 2024
Division of Endocrinology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390-8537, USA.
Eur J Immunol
December 2024
Translational Immunology Research Program, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Pediatr Dermatol
September 2024
Department of Dermatology & Venereology, All India Institute of Medical Sciences, New Delhi, India.
Indian J Pediatr
December 2024
Department of Pediatrics, Penteli Children's Hospital, Athens, Greece.
J Clin Immunol
August 2024
Laboratory of Human Immunology and Infectious Diseases, Graduate Institute of Clinical Medical Sciences, Chang Gung University, No. 259, Wenhua 1st Rd., Guishan District, Taoyuan City, 33302, Taiwan.
Am J Gastroenterol
December 2024
Division of Digestive and Liver Diseases, Department of Medicine, Columbia University, New York, New York, USA.
Front Immunol
August 2024
Central Laboratory, St. Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
Clin Immunol
August 2024
Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China. Electronic address:
Clin Case Rep
June 2024
Family and Community Medicine Department College of Medicine, King Khalid University Abha Saudi Arabia.
J Clin Immunol
May 2024
National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Children's Hospital of Chongqing Medical University, Chongqing, China.
J Clin Immunol
May 2024
Department of Child Health and Development, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8519, Japan.
Infect Drug Resist
May 2024
Laboratory of Medical Mycology, Jining No. 1 People's Hospital, Jining, Shandong Province, People's Republic of China.
Int J Infect Dis
July 2024
Department of Dermatology and Allergology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
J Clin Endocrinol Metab
April 2024
Department of Endocrinology, Diabetology and Metabolism, Huriez Hospital, Lille University Hospital, F-59000 Lille, France.
JAMA Dermatol
May 2024
Department of Medical Mycology, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, Jiangsu, China.
J Clin Immunol
April 2024
Department of Clinical and Experimental Sciences, Department of Pediatrics, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy.